KIT mutation analysis in mast cell neoplasms: Recommendations of the European Competence Network on Mastocytosis

Leukemia

Volumn 29, Issue 6, 2015, Pages 1223-1232

  Arock, M ^a,b   Sotlar, K ^c   Akin, C ^d   Broesby Olsen, S ^e   Hoermann, G ^f   Escribano, L ^g   Kristensen, T K ^e   Kluin Nelemans, H C ^h   Hermine, O ⁱ   Dubreuil, P ^j,k,l,m   Sperr, W R ^f   Hartmann, K ⁿ   Gotlib, J ^o   Cross, N C P ^p   Haferlach, T ^q   Garcia Montero, A ^g   Orfao, A ^g   Schwaab, J ^r   Triggiani, M ^s   Horny, H P ^c   Metcalfe, D D ^t   Reiter, A ^r   Valent, P ^f   more..

^a Ecole Normale Superieure de Cachan   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY OF MUNICH   (Germany)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g CSIC   (Spain)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

^j AIX MARSEILLE UNIVERSITY   (France)

^k INSTITUT PAOLI CALMETTES   (France)

^l AIX MARSEILLE UNIVERSITY   (France)

^m CNRS   (France)

ⁿ UNIVERSITY OF COLOGNE   (Germany)

^o STANFORD CANCER INSTITUTE   (United States)

^p UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^q MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^r UNIVERSITY OF MANNHEIM   (Germany)

^s UNIVERSITY OF SALERNO   (Italy)

^t NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

STEM CELL FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR; TYROSINE KINASE RECEPTOR KIT; UNCLASSIFIED DRUG;

ADULT DISEASE; ALGORITHM; ALLELE; CHILDHOOD DISEASE; CONSENSUS; EARLY DIAGNOSIS; EUROPEAN; FALSE NEGATIVE RESULT; FOLLOW UP; GENE IDENTIFICATION; GENETIC SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOCYTE; MAST CELL; MAST CELL LEUKEMIA; MAST CELL NEOPLASM; MASTOCYTOSIS; MUTATIONAL ANALYSIS; NEOPLASM; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SARCOMA; SYSTEMIC MASTOCYTOSIS; ANIMAL; EUROPE; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ANIMALS; DNA MUTATIONAL ANALYSIS; EUROPE; HUMANS; MAST CELLS; MASTOCYTOSIS; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84930573118     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.24     Document Type: Review

References (97)

1. Krishnaswamy G, Ajitawi O, Chi DS. The human mast cell: an overview. Methods Mol Biol 2006; 315: 13-34.
2. Miettinen M, Lasota J. KIT. (CD117): A review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005; 13: 205-220.
3. Ashman LK, Ferrao P, Cole SR, Cambareri AC. Effects of mutant c-kit in early myeloid cells. Leuk Lymphoma 2000; 37: 233-243.
4. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 1999; 94: 2333-2342.
5. Matarraz S, Lopez A, Barrena S, Fernandez C, Jensen E, Flores J et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia 2008; 22: 1175-1183.
6. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, Sanchez-Munoz L, Alvarez-Twose I, Nunez R et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol 2010; 125: 719-726.
7. Chang A, Tung RC, Schlesinger T, Bergfeld WF, Dijkstra J, Kahn TA. Familial cutaneous mastocytosis. Pediatr Dermatol 2001; 18: 271-276.
8. Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal. Int Arch Allergy Immunol 2012; 157: 215-225.
9. Briley LD, Phillips CM. Cutaneous mastocytosis: A review focusing on the pediatric population. Clin Pediatr (Phila) 2008; 47: 757-761.
10. Vano-Galvan S, Alvarez-Twose I, De las Heras E, Morgado JM, Matito A, Sanchez-Munoz L et al. Dermoscopic features of skin lesions in patients with mastocytosis. Arch Dermatol 2011; 147: 932-940.
11. Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 2010; 3: 497-516.
12. Fried AJ, Akin C. Primary mast cell disorders in children. Curr Allergy Asthma Rep 2013; 13: 693-701.
13. Wang SA, Hutchinson L, Tang G, Chen SS, Miron PM, Huh YO et al. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol 2013; 88: 219-224.
14. Metcalfe DD. Mast cells and mastocytosis. Blood 2008; 112: 946-956.
15. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leuk Res 2001; 25: 603-625.
16. Valent P, Horny H-P, Li CY. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization (WHO) Classification of Tumours, vol. 1. IARC Press edn: Lyon, France, 2001; pp 291-302.
17. Horny HP, Akin C, Metcalfe DD, Escribano L, Bennett JM, Valent P, Bain BJ. Mastocytosis (mast cell disease). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) World Health Organization (WHO) Classification of Tumours. IARC Press edn: Lyon, France, 2008; pp 54-63.
18. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435-453.
19. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 2366-2372.
20. Sanchez-Munoz L, Alvarez-Twose I, Garcia-Montero AC, Teodosio C, Jara-Acevedo M, Pedreira CE et al. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol 2011; 24: 1157-1168.
21. Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014; 93: 81-88.
22. Kristensen T, Vestergaard H, Bindslev-Jensen C, Moller MB, Broesby-Olsen S. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol 2014; 89: 493-498.
23. Bodemer C, Hermine O, Palmerini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010; 130: 804-815.
24. Tan A, Westerman D, McArthur GA, Lynch K, Waring P, Dobrovic A. Sensitive detection of KIT D816V in patients with mastocytosis. Clin Chem 2006; 52: 2250-2257.
25. Kristensen T, Broesby-Olsen S, Vestergaard H, Bindslev-Jensen C, Moller MB. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. Eur J Haematol 2012; 89: 42-46.
26. Hoermann G, Gleixner KV, Dinu GE, Kundi M, Greiner G, Wimazal F et al. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy 2014; 69: 810-813.
27. Bibi S, Langenfeld F, Jeanningros S, Brenet F, Soucie E, Hermine O et al. Molecular defects in mastocytosis: KIT and beyond KIT. Immunol Allergy Clin North Am 2014; 34: 239-262.
28. Valent P, Akin C, Sperr WR, Mayerhofer M, Fodinger M, Fritsche-Polanz R et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005; 46: 35-48.
29. Escribano L, Alvarez-Twose I, Sanchez-Munoz L, Garcia-Montero A, Nunez R, Almeida J et al. Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009; 124: 514-521.
30. Valent P, Arock M, Bischoff SC, Buhring HJ, Brockow K, Escribano L et al. The European Competence Network on Mastocytosis (ECNM). Wien Klin Wochenschr 2004; 116: 647-651.
31. Valent P, Arock M, Bonadonna P, Brockow K, Broesby-Olsen S, Escribano L et al. European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wien Klin Wochenschr 2012; 124: 807-814.
32. Giebel LB, Strunk KM, Holmes SA, Spritz RA. Organization and nucleotide sequence of the human KIT (mast/stem cell growth factor receptor) proto-oncogene. Oncogene 1992; 7: 2207-2217.
33. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. The protooncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988; 335: 88-89.
34. Cheng P, Chen H, Liu SR, Pu XY, A ZC. SNPs in KIT and KITLG genes may be associated with oligospermia in Chinese population. Biomarkers 2013; 18: 650-654.
35. Nagata H, Worobec AS, Metcalfe DD. Identification of a polymorphism in the transmembrane domain of the protooncogene c-kit in healthy subjects. Exp Clin Immunogenet 1996; 13: 210-214.
36. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12: 312-314.
37. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007; 138: 12-30.
38. Georgin-Lavialle S, Lhermitte L, Dubreuil P, Chandesris MO, Hermine O, Damaj G. Mast cell leukemia. Blood 2013; 121: 1285-1295.
39. Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006; 30: 373-378.
40. Wasag B, Niedoszytko M, Piskorz A, Lange M, Renke J, Jassem E et al. Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis. Exp Hematol 2011; 39: 859-865.
41. Hoffmann KM, Moser A, Lohse P, Winkler A, Binder B, Sovinz P et al. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood 2008; 112: 1655-1657.
42. Wohrl S, Moritz KB, Bracher A, Fischer G, Stingl G, Loewe R. A c-kit mutation in exon 18 in familial mastocytosis. J Invest Dermatol 2013; 133: 839-841.
43. Pollard WL, Beachkofsky TM, Kobayashi TT. Novel R634W c-kit mutation identified in familial mastocytosis. Pediatr Dermatol 2014; e-pub ahead of print 22 September 2014; doi:10. 1111/pde. 12381.
44. Broesby-Olsen S, Kristensen TK, Moller MB, Bindslev-Jensen C, Vestergaard H. Adult-onset systemic mastocytosis in monozygotic twins with KIT D816V and JAK2 V617F mutations. J Allergy Clin Immunol 2012; 130: 806-808.
45. Zanotti R, Simioni L, Garcia-Montero AC, Perbellini O, Bonadonna P, Caruso B et al. Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis. J Allergy Clin Immunol 2013; 131: 605-607.
46. Sperr WR, Horny HP, Valent P. Spectrum of associated clonal hematologic nonmast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol 2002; 127: 140-142.
47. Stoecker MM, Wang E. Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease: A clinicopathologic review. Arch Pathol Lab Med 2012; 136: 832-838.
48. Valent P. Mastocytosis: A paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res 2013; 3: 159-172.
49. Piazza R, Redaelli S, Pirola A, Valletta S, Magistroni V, Cross NCP et al. Recurrent KIT D816V mutation in atypical chronic myeloid leukemia. 19th Congress of the European Hematology Association, 12-15 June 2014, Milan, Italy 2014.
50. Stellmacher F, Sotlar K, Balleisen L, Valent P, Horny HP. Bone marrow mastocytosis associated with IgM kappa plasma cell myeloma. Leuk Lymphoma 2004; 45: 801-805.
51. Horny HP, Sotlar K, Stellmacher F, Valent P, Grabbe J. An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL). J Clin Pathol 2006; 59: 264-268.
52. Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, Bultmann B et al. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol 2010; 220: 586-595.
53. Fritsche-Polanz R, Fritz M, Huber A, Sotlar K, Sperr WR, Mannhalter C et al. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. Mol Oncol 2010; 4: 335-346.
54. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002; 1: 1115-1124.
55. Lasota J. Not all c-kit mutations can be corrected by imatinib. Lab Invest 2007; 87: 317.
56. Foster R, Griffith R, Ferrao P, Ashman L. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model 2004; 23: 139-152.
57. Laine E, Chauvot de Beauchene I, Perahia D, Auclair C, Tchertanov L. Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms. PLoS Comput Biol 2011; 7: e1002068.
58. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van 't Wout JW, Verhoef G, Gerrits WB et al. Cladribine therapy for systemic mastocytosis. Blood 2003; 102: 4270-4276.
59. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, Koller E, Sperr WR, Lechner K et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004; 28: 249-257.
60. Gotlib J, DeAngelo DJ, George TI, Corless CL, Linder A, Langford C et al. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial. Blood 2010; 116: 316.
61. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O et al. KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: results of a planned interim analysis of the global CPKC412D2201 trial. Blood 2012; 120: 799.
62. Mital A, Piskorz A, Lewandowski K, Wasag B, Limon J, Hellmann A. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol 2011; 86: 531-535.
63. Alvarez-Twose I, Gonzalez P, Morgado JM, Jara-Acevedo M, Sanchez-Munoz L, Matito A et al. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. J Clin Oncol 2012; 30: e126-e129.
64. Valent P, Escribano L, Broesby-Olsen S, Hartmann K, Grattan C, Brockow K et al. Proposed diagnostic algorithm for patients with suspected mastocytosis: A proposal of the European Competence Network on Mastocytosis. Allergy 2014; 69: 1267-1274.
65. Corless CL, Harrell P, Lacouture M, Bainbridge T, Le C, Gatter K et al. Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. J Mol Diagn 2006; 8: 604-612.
66. Sotlar K, Escribano L, Landt O, Mohrle S, Herrero S, Torrelo A et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003; 162: 737-746.
67. Schumacher JA, Elenitoba-Johnson KS, Lim MS. Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR. J Clin Pathol 2008; 61: 109-114.
68. Kristensen T, Vestergaard H, Moller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn 2011; 13: 180-188.
69. Sotlar K, Marafioti T, Griesser H, Theil J, Aepinus C, Jaussi R et al. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol Pathol 2000; 53: 188-193.
70. Sotlar K, Fridrich C, Mall A, Jaussi R, Bultmann B, Valent P et al. Detection of c-kit point mutation Asp-816-4 Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk Res 2002; 26: 979-984.
71. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, Alvarez-Twose I, Sanchez-Munoz L, Almeida J et al. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis. Leukemia 2012; 26: 951-958.
72. Sotlar K. c-kit mutational analysis in paraffin material. Methods Mol Biol 2013; 999: 59-78.
73. Mattocks CJ, Morris MA, Matthijs G, Swinnen E, Corveleyn A, Dequeker E et al. A standardized framework for the validation and verification of clinical molecular genetic tests. Eur J Hum Genet 2010; 18: 1276-1288.
74. Travis WD, Li CY. Pathology of the lymph node and spleen in systemic mast cell disease. Mod Pathol 1988; 1: 4-14.
75. Diebold J, Riviere O, Gosselin B, Janin-Mercier A, Canelhas A, Le Tourneau A et al. Different patterns of spleen involvement in systemic and malignant mastocytosis. A histological and immunohistochemical study of three cases. Virchows Arch A Pathol Anat Histopathol 1991; 419: 273-280.
76. Metcalfe DD. The liver, spleen, and lymph nodes in mastocytosis. J Invest Dermatol 1991; 96: 45S-46 S.
77. Horny HP, Ruck MT, Kaiserling E. Spleen findings in generalized mastocytosis. A clinicopathologic study. Cancer 1992; 70: 459-468.
78. Mican JM, Di Bisceglie AM, Fong TL, Travis WD, Kleiner DE, Baker B et al. Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology 1995; 22: 1163-1170.
79. Horny HP, Ruck P, Krober S, Kaiserling E. Systemic mast cell disease (mastocytosis). General aspects and histopathological diagnosis. Histol Histopathol 1997; 12: 1081-1089.
80. Smith JD, Lazarchick J. Systemic mast cell disease with marrow and splenic involvement associated with chronic myelomonocytic leukemia. Leuk Lymphoma 1999; 32: 391-394.
81. Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000; 14: 579-623.
82. Parwaresch MR, Horny HP, Lennert K. Tissue mast cells in health and disease. Pathol Res Pract 1985; 179: 439-461.
83. Horny HP, Parwaresch MR, Lennert K. Bone marrow findings in systemic mastocytosis. Hum Pathol 1985; 16: 808-814.
84. Wimazal F, Schwarzmeier J, Sotlar K, Simonitsch I, Sperr WR, Fritsche-Polanz R et al. Splenic mastocytosis: report of two cases and detection of the transforming somatic C-KIT mutation D816V. Leuk Lymphoma 2004; 45: 723-729.
85. Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001; 113: 357-364.
86. Kristensen T, Broesby-Olsen S, Vestergaard H, Bindslev-Jensen C, Moller MB. KIT D816V mutation-positive cell fractions in lesional skin biopsies from adults with systemic mastocytosis. Dermatology 2013; 226: 233-237.
87. Kristensen T, Broesby-Olsen S, Vestergaard H, Bindslev-Jensen C, Moller MB. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis. Eur J Haematol 2013; 91: 106-111.
88. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103: 3222-3225.
89. Yang Y, Letard S, Borge L, Chaix A, Hanssens K, Lopez S et al. Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood 2010; 116: 1114-1123.
90. Georgin-Lavialle S, Lhermitte L, Suarez F, Yang Y, Letard S, Hanssens K et al. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. Eur J Haematol 2012; 89: 47-52.
91. Soucie E, Brenet F, Dubreuil P. Molecular basis of mast cell disease. Mol Immunol 2014; 63: 55-60.
92. Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013; 122: 2460-2466.
93. Hussein K, Horny HP, Busche G, Gorner M, Gohring G, Kreipe H et al. Systemic mastocytosis (SM) with associated BCR-ABL-positive myelogenous leukaemia (SM-AHNMD): evidence that mast cells do not belong to the leukaemic clone. Leukemia 2011; 25: 1050-1053.
94. Joris M, Georgin-Lavialle S, Chandesris MO, Lhermitte L, Claisse JF, Canioni D et al. Mast cell leukaemia: c-KIT mutations are not always positive. Case Rep Hematol 2012; 2012: 517546.
95. Ryan RJ, Akin C, Castells M, Wills M, Selig MK, Nielsen GP et al. Mast cell sarcoma: A rare and potentially under-recognized diagnostic entity with specific therapeutic implications. Mod Pathol 2013; 26: 533-543.
96. Kim YS, Wu H, Pawlowska AB, Bautista-Quach MA, Huang Q, Gaal K et al. Pediatric mast cell sarcoma of temporal bone with novel L799F (2395 C4T) KIT mutation, mimicking histiocytic neoplasm. Am J Surg Pathol 2013; 37: 453-458.
97. Georgin-Lavialle S, Aguilar C, Guieze R, Lhermitte L, Bruneau J, Fraitag S et al. Mast cell sarcoma: A rare and aggressive entity-report of two cases and review of the literature. J Clin Oncol 2013; 31: e90-e97.